News | March 10, 2026
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
The first of four planned modules at the new plant is expected to come online by summer 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Subscribe To Our Newsletter & Stay Updated
